Excellence in Oncology and Cancer Research in Beijing
Presented by
Introduction
Foreword
from Prof. Jie He
Beijing has always been a cancer research hub, which contributed innovative ideas to many hot topics at the research frontier, playing a leading role in international and domestic studies.
Cell Press and the Beijing Municipal Science and Technology Commission have collected 10 representative papers published by Chinese scholars in the Cell Press journals, conducted in-depth interviews with extraordinary scientists in Beijing, and analyzed cancer research development in the area.
Let us continue to strive with faith and courage to work towards a healthy China and contribute to the innovation and development of cancer research worldwide!
Introduction
Foreword
from Prof. Jie He
The Galaxy Soho Central Beijing
People
The minds that drive the discoveries
As a prominent talent hub, Beijing attracts brilliant minds in oncology and cancer research. These experts have propelled the advance in scientific discoveries and clinical care, both as their personal endeavor and through collaborative efforts in the community.
Qimin Zhan, M.D.
President of Peking University Health Science Center, President of Peking University Shenzhen Graduate School
“You need not only a wealth of medical knowledge and superb medical skills, but also a love for humanity.”Zemin Zhang, Ph.D.
Professor, School of Life Sciences, Peking University
“Beijing has a wealth of clinical resources. On top of that, doctors and patients are highly cooperative.”Wu Chen, Ph.D.
Professor, National Cancer Hospital, Chinese Academy of Medical Sciences
“We have to be with the patients to understand what they need first."Xin Lin, Ph.D.
Professor and Chairman, Department of Basic Medical Sciences, Tsinghua University School of Medicine
As a cancer patient himself, he has a deeper understanding of patients’ expectations.Yonghui Zhang, Ph.D.
Associate Professor, School of Pharmaceutical Sciences, Tsinghua University
Zhang defines himself as “a scientist studying tumor immunity through the lens of chemistry.”Meng Chen, Ph.D.
Deputy Director of National Cancer Data Center, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
“The development and utilization of big data relies on having a high-quality database."
The Temple of Heaven Beijing
Papers
The discoveries that advance the science
The exceptional discoveries in oncology and cancer research made by scientists and clinicians in Beijing are captured by a suite of Cell Press journals, among which we highlight several representatives showcasing the diverse topics and broad scope of these achievements.
Hover over journal covers on the left to learn more about selected papers.
Cancer Cell
VOLUME 33, ISSUE 3, P480-494.E7, 03/12/2018,
Tumor-Repopulating Cells Induce PD-1 Expression in CD8+ T Cells by Transferring Kynurenine and AhR Activation
Read moreCell
VOLUME 175, ISSUE 4, P1059-1073.E21, 11/01/2018,
The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery
Read moreCell
VOLUME 175, ISSUE 6, P1665-1678.E18, 11/29/2018,
Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor Cell
Read moreCell Reports
VOLUME 27, ISSUE 6, P1934-1947.E5, 05/07/2019,
Dissecting the Single-Cell Transcriptome Network Underlying Gastric Premalignant Lesions and Early Gastric Cancer
Read moreCancer Cell
VOLUME 35, ISSUE 6, P932-947.E8, 06/10/2019,
Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes
Read moreCell Reports
VOLUME 30, ISSUE 6, P1780-1797.E6, 02/11/2020,
Secreted Pyruvate Kinase M2 Promotes Lung Cancer Metastasis through Activating the Integrin Beta1/FAK Signaling Pathway
Read moreCell
VOLUME 181, ISSUE 2, P442-459.E29, 04/16/2020,
Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer
Read moreCell
VOLUME 182, ISSUE 1, P245-261.E17, 07/09/2020,
Integrative Proteomic Characterization of Human Lung Adenocarcinoma
Read moreCancer Cell
VOLUME 38, ISSUE 4, P551-566.E11, 10/12/2020,
Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies
Read moreCell Reports
VOLUME 33, ISSUE 3, 108278, 10/20/2020,
PPARα Inhibition Overcomes Tumor-Derived Exosomal Lipid-Induced Dendritic Cell Dysfunction
Read more
CCTV Headquarters Beijing Central Business District
Performance
The science that accelerates progress
Celebrating Beijing’s role as a global center of impactful oncology and cancer research. The diagrams below chart the city’s scholarly outputs and activities across this critical medical discipline.
Oncology and cancer research output in Beijing grew 277% from 873 publications in 2010 to 3,287 in 2020
100 institutions in Beijing have publications within the disciplines of oncology and cancer research
Between 2010 and 2018 the NFSC awarded 155 million USD in grants to cancer research in Bejjng
